Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

NCT06083883 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Synovial Sarcoma
Myxoid/Round Cell Liposarcoma

Interventions

DRUG: Fludarabine phosphate
DRUG: NY-ESO-1 TCR/IL-15 NK
DRUG: Cyclophosphamide

Sponsor

M.D. Anderson Cancer Center